Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.

Lucar O, Sadjo Diallo M, Bayard C, Samri A, Tarantino N, Debré P, Thiébaut R, Brun-Vézinet F, Matheron S, Cheynier R, Vieillard V; ANRS CO5 IMMUNOVIR-2 Study group.

AIDS. 2019 Jan 27;33(1):23-32. doi: 10.1097/QAD.0000000000002061.

PMID:
30325780
2.

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.

Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, Marcenaro E.

Oncoimmunology. 2015 Jan 22;4(4):e1001224. eCollection 2015 Apr.

3.

Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.

Xu X, Li Y, Gauthier L, Chen Q, Vivier E, Mariuzza RA.

Acta Crystallogr F Struct Biol Commun. 2015 Jun;71(Pt 6):697-701. doi: 10.1107/S2053230X15006755. Epub 2015 May 20.

4.

Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.

Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A.

Blood. 2013 Aug 1;122(5):684-93. doi: 10.1182/blood-2013-02-482513. Epub 2013 Jun 25.

5.

The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Textor S, Bossler F, Henrich KO, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K, Golfier S, Witzens-Harig M, Cerwenka A.

Oncoimmunology. 2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul.

6.

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, Cerwenka A.

Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.

7.

Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Marras F, Nicco E, Bozzano F, Di Biagio A, Dentone C, Pontali E, Boni S, Setti M, Orofino G, Mantia E, Bartolacci V, Bisio F, Riva A, Biassoni R, Moretta L, De Maria A.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11970-5. doi: 10.1073/pnas.1302090110. Epub 2013 Jul 1.

8.

Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.

Li Y, Wang Q, Mariuzza RA.

J Exp Med. 2011 Apr 11;208(4):703-14. doi: 10.1084/jem.20102548. Epub 2011 Mar 21.

9.

NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.

Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, Wang G, Lin D.

PLoS One. 2015 Aug 4;10(8):e0134568. doi: 10.1371/journal.pone.0134568. eCollection 2015.

10.

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.

Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M.

J Immunol. 2012 Nov 15;189(10):5037-46. doi: 10.4049/jimmunol.1201321. Epub 2012 Oct 12.

11.

Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.

Xu X, Narni-Mancinelli E, Cantoni C, Li Y, Guia S, Gauthier L, Chen Q, Moretta A, Vély F, Eisenstein E, Rangarajan S, Vivier E, Mariuzza RA.

J Mol Biol. 2016 Nov 6;428(22):4457-4466. doi: 10.1016/j.jmb.2016.09.011. Epub 2016 Sep 20.

PMID:
27663271
12.

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Peipp M, Derer S, Lohse S, Staudinger M, Klausz K, Valerius T, Gramatzki M, Kellner C.

Oncotarget. 2015 Oct 13;6(31):32075-88. doi: 10.18632/oncotarget.5135.

13.

Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.

Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, Lambotte O, Meyer L, Gougeon ML, Zitvogel L.

Oncoimmunology. 2013 Mar 1;2(3):e23472.

14.

Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma.

Mantovani S, Oliviero B, Lombardi A, Varchetta S, Mele D, Sangiovanni A, Rossi G, Donadon M, Torzilli G, Soldani C, Porta C, Pedrazzoli P, Chiellino S, Santambrogio R, Opocher E, Maestri M, Bernuzzi S, Rossello A, Clément S, De Vito C, Rubbia-Brandt L, Negro F, Mondelli MU.

Hepatology. 2018 Aug 28. doi: 10.1002/hep.30235. [Epub ahead of print]

PMID:
30153337
15.

Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56-CD16+ Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection.

Zulu MZ, Naidoo KK, Mncube Z, Jaggernath M, Goulder PJR, Ndung'u T, Altfeld M, Thobakgale CF.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1205-1213. doi: 10.1089/AID.2017.0095. Epub 2017 Sep 21.

PMID:
28810810
16.

Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Herrmann J, Berberich H, Hartmann J, Beyer S, Davies K, Koch J.

J Biol Chem. 2014 Jan 10;289(2):765-77. doi: 10.1074/jbc.M113.514786. Epub 2013 Nov 25.

17.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
18.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

19.

Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.

Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U.

Gut. 2006 Jun;55(6):869-77. Epub 2005 Dec 1.

20.

Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20.

Charpak-Amikam Y, Kubsch T, Seidel E, Oiknine-Djian E, Cavaletto N, Yamin R, Schmiedel D, Wolf D, Gribaudo G, Messerle M, Cicin-Sain L, Mandelboim O.

Sci Rep. 2017 Aug 17;7(1):8661. doi: 10.1038/s41598-017-08866-2.

Supplemental Content

Support Center